Skip to main content
Top
Literature
2.
go back to reference Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071–2078. https://doi.org/10.1007/s00467-017-3718-0 CrossRefPubMed Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K, Rituximab for Childhood-Onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071–2078. https://​doi.​org/​10.​1007/​s00467-017-3718-0 CrossRefPubMed
Metadata
Title
Response to “Predictors of rituximab-related neutropenia in Japanese children with steroid-dependent nephrotic syndrome”
Authors
Tim Ulinski
Jean Daniel Delbet
Publication date
01-07-2019
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 7/2019
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-019-04239-1

Other articles of this Issue 7/2019

Pediatric Nephrology 7/2019 Go to the issue